Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p66
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 66/191)
Character Range: 10249009–10262063

condition must be associated with cytotoxic chemotherapy being used to treat malignancy; AND
                                                                                                                                                                                                                               The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on day 1 of a chemotherapy cycle; AND
                                                                                                                                                                                                                               Patient must be scheduled to be administered a chemotherapy regimen that includes either carboplatin or oxaliplatin.
                                                                                                                                                                                                                               No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy.
                                                                                                                                                                                                                               Concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle.
C6387               P6387          CN6387           Naproxen                                                                                                                                                                   Bone pain
                                                                                                                                                                                                                               The condition must be due to malignant disease.
C6390               P6390          CN6390           Octreotide                                                                                                                                                                 Functional carcinoid tumour                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 6390
                                                                                                                                                                                                                               The condition must be causing intractable symptoms; AND
                                                                                                                                                                                                                               Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents; AND
                                                                                                                                                                                                                               Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate; AND
                                                                                                                                                                                                                               The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy.
                                                                                                                                                                                                                               Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.
C6394               P6394          CN6394           Desferrioxamine                                                                                                                                                            Disorders of erythropoiesis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 6394
                                                                                                                                                                                                                               The condition must be associated with treatment-related chronic iron overload.
C6395               P6395          CN6395           Terbinafine                                                                                                                                                                Onychomycosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures
                                                                                                                                                                                                                               The condition must be proximal or extensive (greater than 80% nail involvement); AND
                                                                                                                                                                                                                               Patient must have failed to respond to topical treatment; AND
                                                                                                                                                                                                                               The condition must be due to dermatophyte infection proven by microscopy and confirmed by an Approved Pathology Provider.  or
                                                                                                                                                                                                                               The condition must be due to dermatophyte infection proven by culture and confirmed by an Approved Pathology Provider.
                                                                                                                                                                                                                               The date of the pathology report must be provided at the time of application and must not be more than 12 months old
C6403               P6403          CN6403           Deferiprone                                                                                                                                                                Iron overload                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures - Streamlined Authority Code 6403
                                                                                                                                                                                                                               Patient must have thalassaemia major; AND
                                                                                                                                                                                                                               Patient must be one in whom desferrioxamine therapy has proven ineffective.
C6404               P6404          CN6404           Terbinafine                                                                                                                                                                Dermatophyte infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Compliance with Authority Required procedures
                                                                                                                                                                                                                               Patient must have failed to respond to topical treatment;
                                                                                                                                                                                                                               Patient must be an Aboriginal or a Torres Strait Islander person.
C6409               P6409          CN6409           Leuprorelin                                                                                                                                                                Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate

                                                    Triptorelin

C6410               P6410          CN6410           Liothyronine                                                                                                                                                               Hypothyroidism                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Compliance with Authority Required procedures - Streamlined Authority Code 6410
                                                                                                                                                                                                                               The treatment must be for replacement therapy; AND
                                                                                                                                                                                                                               Patient must